The global oncolytic adenovirus market is expected to garner a market value of USD 121.30 Billion in 2023 and is expected to accumulate a market value of USD 250 Billion by registering a CAGR of 7.5% in the forecast period 2023 to 2033. Growth of the oncolytic adenovirus market can be attributed to the Increasing prevalence of oncology globally coupled with a surge in Research and Development efforts to develop novel oncology therapeutics. These are the major driving factors for the market. The market for oncolytic adenovirus registered a CAGR of 4.9% in the historical period 2018 to 2022
Moreover, the presence of various organizations that support immunotherapy research is also expected to fuel market growth. For instance, Parker Institute for Cancer Immunotherapy collaborated with researchers and industry leaders to develop breakthrough immune therapies for cancer.
According to the Global Cancer Observatory, the US reported around 2,281,658 cancer cases in 2020 and 612,390 cancer-related deaths. The most common malignancies affecting the US population are breast, prostate, lung, and colorectal. In addition, according to the Cancer Council, Australia reported 150,000 new cancer cases with 50,000 deaths in 2020. Thus, the surge in the prevalence of malignant tumor cases is anticipated to accelerate market expansion in the coming years.
Report Attribute | Details |
---|---|
Expected Market Value (2023) | USD 121.30 Billion |
Anticipated Forecast Value (2033) | USD 250 Billion |
Projected Growth Rate (2023 to 2033) | 7.5% CAGR |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
According to market research and competitive intelligence provider Future Market Insights- the market for oncolytic adenovirus reflected a value of 4.9% during the historical period, 2017 to 2022.
The increasing prevalence of different types of cancers is a significant factor driving the market's growth. In addition, the presence of various immunotherapies to treat cancer at different stages in creating a positive demand for oncolytic adenovirus. Furthermore, the COVID-19 pandemic affected the research and development activities related to oncolytic adenovirus due to the disruption in the supply chain demand globally.
Thus, the market for Oncolytic adenovirus is expected to register a CAGR of 7.5% in the forecast period 2023 to 2033.
Improving patient outcomes by advancing the science and application of oncolytic adenovirus
The presence of various government and non-government organizations that create awareness and promote research is augmenting market expansion. For instance, Cancer Research Institute funded more than 120 clinical trials and invested around USD 474 Billion in research. Moreover, the Society for Immunotherapy of Cancer(SITC) is engaged in improving patient outcomes by advancing the science and application of oncolytic adenovirus. These organizations are working with scientists and researchers to discover novel treatment regimens of immune therapy.
Furthermore, increasing funding for the development of novel treatments is expected to boost Research and Development activities to develop cancer immunotherapy. For instance, in June 2022, Stanford scientists received USD 13 Billion from Cancer Grand Challenges, a funding initiative by Cancer Research UK and the US National Cancer Institute. This funding is awarded for the development of next-generation immunotherapies, the study of extrachromosomal DNA, and the investigation of early-stage malignancies.
Increasing approval of novel immunotherapies is anticipated to propel the market growth over the forecast period. From 2020 to 2022, the USA FDA has approved various anti-PD-1/L1 antibodies such as nivolumab, atezolizumab, avelumab, dostarlimab, and others for the treatment of NSCLC, renal cell carcinoma, melanoma, breast, prostate malignancies, and others. The higher approvals of immunotherapeutic agents have propelled the market growth.
Strategic initiatives by leading players propelling the market growth
Various Strategic initiatives undertaken by leading players are also expected to facilitate the market demand. For instance, in August 2022, BioNTech SE and Genmab A/S expanded their strategic collaboration for the development and launch of new immune therapies for the treatment of various cancer forms. Moreover, in March 2022, Merck & Co., Inc announced the approval of KEYTRUDA from the US FDA. KEYTRUDA is an anti-PD-1 therapy for treating advanced endometrial carcinoma.
However, side effects associated with immunotherapy will likely hamper the cancer treatment prescription rate. The available therapies are associated with several adverse effects, such as pain, insomnia, fatigue, nausea, and gastrointestinal conditions. These adverse effects impact the overall quality of life of patients and the management of these adverse effects incurs extra costs. In addition, prolonged consumption of immunotherapeutic drugs may cause severe damage to the organs and increase the incidence of organ failure cases.
Antiviral immune response creating challenges for the oncolytic adenovirus market
Although oncolytic adenovirus has remarkable antitumor potency, it is confronted with tough challenges such as antiviral immune response and obstruction of the tumor microenvironment (TME). This has led to a significant debate on the efficiency and application of oncolytic adenovirus for cancer treatment.
Furthermore, the time taken for approval of therapies and medications for cancer is derailing the progress of the market. In addition, the efficiency of drugs and their long-lasting impact is still being tested. All these factors are hampering the growth of the oncolytic adenovirus market.
Government and non-government organizations supporting research activities for oncolytic adenovirus in North America
In 2022, North America led the overall market in terms of revenue due to the presence of a large number of leading players coupled with various Strategic initiatives undertaken by them. Moreover, the increase in disease prevalence, various government and non-government organizations promoting research activities for cancer immunotherapy, and the increasing approval of novel drugs are fueling the regional market growth. For instance, in April 2022, the US FDA approved Opdivo (nivolumab) for treating NSCLC in adult patients.
Thus, North America is expected to possess a 43% market share for the oncolytic adenovirus market in 2023.
Investments in research and healthcare infrastructure create lucrative opportunities for the oncolytic adenovirus market
Asia Pacific is projected to witness the fastest growth rate over the forecast period. The increase in the geriatric population, a large patient base of targeted diseases, and improving healthcare infrastructure are some of the primary factors driving the growth.
Moreover, the rising regulatory approvals of immune therapies in the region are also contributing region’s expansion. For instance, from 2020 to 2022, the National Medical Products Administration of China approved Pembrolizumab and Durvalumab to treat esophageal cancer and SCLC.
Thus, Asia Pacific is expected to possess a 39% market share for the oncolytic adenovirus market in 2023.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Product approval for treating lung cancer boosting segment growth
The rising prevalence of lung malignancies, increasing adoption of immunotherapy, rise in awareness programs, and presence of a robust pipeline of investigational candidates are some of the key factors expected to drive the segment's growth. Furthermore, rising product approval and product launches fueling the demand forward. For instance, in October 2021, the US FDA approved Tecentriq (atezolizumab) to treat stage II and stage III NSCLC.
Thus, lung cancer is expected to possess a 35% market share for oncolytic adenovirus in 2023.
Key players in the oncolytic adenovirus market are Amgen, Sorrento Therapeutics, Transgene SA, Oncolys BioPharma, Targovax, Lokon Pharma, Vyriad, TILT Biotherapeutics, CG Oncology Inc, VCNBiosciences, DNAtrix, Replimune Group Inc
Report Attribute | Details |
---|---|
Market Value in 2023 | USD 121.30 Billion |
Market Value in 2033 | USD 250 Billion |
Growth Rate | CAGR of 7.5% from 2023 to 2033 |
Base Year for Estimation | 2021 |
Historical Data | 2018 to 2022 |
Forecast Period | 2023 to 2033 |
Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered | Type, Application, Region |
Regions Covered | North America; Latin America; Western Europe; Eastern Europe; Asia Pacific Excluding Japan; Japan; Middle East and Africa (MEA) |
Key Countries Profiled | The USA, Canada, Brazil, Argentina, Germany, The UK, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, Association of Southeast Asian Nations, GCC Countries, South Africa |
Key Companies Profiled | Amgen; Sorrento Therapeutics; Transgene SA; Oncolys BioPharma; Targovax; Lokon Pharma; Vyriad; TILT Biotherapeutics; CG Oncology Inc; VCNBiosciences; DNAtrix; Replimune Group Inc |
Customization | Available Upon Request |
From 2017 to 2022, the oncolytic adenovirus market grew at a CAGR of 4.9%
The global oncolytic adenovirus market is expected to grow with a 7.5% CAGR from 2023 to 2033.
As of 2033, the oncolytic adenovirus market is expected to reach USD 250 Billion
Lung cancer is expected to possess a 35% market share for oncolytic adenovirus in 2023.
North America is expected to possess a 43% market share for the oncolytic adenovirus market in 2023.
Asia Pacific's oncolytic adenovirus market size is expected to possess a 39% market share in 2023.
Estimated Size, 2025 | USD 1,047.9 million |
---|---|
Projected Size, 2035 | USD 2,194.9 million |
Value-based CAGR (2025 to 2035) | 6.8% |
Estimated Size, 2024 | USD 2,861.0 million |
---|---|
Projected Size, 2034 | USD 5,436.8 million |
Value-based CAGR (2024 to 2034) | 6.6% |
Market Estimated Size in 2023 | USD 585.6 million |
---|---|
Projected Market Value in 2033 | USD 1,058.6 million |
Value-based CAGR from 2023 to 2033 | 6.1% |
Market Value (2022) | USD 1,127 Million |
---|---|
Market Forecast Value (2032) | USD 2,145.52 Million |
Market CAGR (2022 to 2032) | 6.65% |
Explore Therapy Area Insights
View ReportsThank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.